Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography

Leukemia Research

Volumn 34, Issue 6, 2010, Pages 702-707

  Davies, Andrea ^a   Hayes, Alison K ^a   Knight, Katy ^b   Watmough, Sarah J ^b   Pirmohamed, Munir ^a   Clark, Richard E ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

CGP 74588; Chronic myeloid leukaemia; Human plasma; Imatinib; Nilotinib; Therapeutic drug monitoring; UV HPLC

Indexed keywords

2 [2 METHYL 5 [4 (1 PIPERAZINYLMETHYL)BENZAMIDO]ANILINO] 4 (3 PYRIDYL)PYRIMIDINE; IMATINIB; NILOTINIB;

ACCURACY; ARTICLE; BLOOD ANALYSIS; CALIBRATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; QUALITY CONTROL; SOLID PHASE EXTRACTION; SPECTRAL SENSITIVITY; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CHEMICAL ANALYSIS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCADIAN RHYTHM; HUMANS; LIMIT OF DETECTION; PIPERAZINES; PLASMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 77952094193     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.11.009     Document Type: Article

References (38)

1. Druker B.J., Guillot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattemann N., Deininger M.W.N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(23):2408-2417.
2. Weisberg E., Manley P.W., Breitenstein W., Brüggen J., Cowan-Jacob S.W., Ray A., Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., Kung A.L., Mestan J., Daley G.Q., Callahan L., Catley L., Cavazza C., Azam M., Neuberg D., Wright R.D., Gilliland D.G., Griffin J.D. Characterisation of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell 2005, 7:129-141.
3. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305(5682):399-401.
4. Christopher L.J., Cui D., Wu C., Luo R., Manning J.A., Bonacorsi S.J., Lago M., Allentoff A., Lee F.Y., McCann B., Galbraith S., Reitberg D.P., He K., Barros A., Blackwood-Chirchir A., Humphreys W.G., Iyer R.A. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 2008, 36(7):1357-1364.
5. Tasigna (nilotinib) [package insert]. East hanover, NJ: Novartis Pharmaceuticals Corporation; October 2007. Accessed 28th April 2009. http://www.fda.gov/cder/foi/label/2007/022068lbl.pdf.
6. O'Hare T., Eide C.A., Deininger M.W. Bcr-Abl kinase domain mutation, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110(7):2242-2249.
7. Bradeen H.A., Eide C.A., O'Hare T., Johnson K.J., Willis S.G., Lee F.Y., Druker B.J., Deininger M.W. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006, 108(7):2332-2338.
8. Burgess M.R., Skaggs B.J., Shah N.P., Lee F.Y., Sawyers C.L. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005, 102(9):3395-3400.
9. + leukemias. Blood 2007, 109(5):2112-2120.
10. Von Mehren M., Reichardt P., Casali P.G., Blay J., Debiec-Rychter M., Dumez H., Cheung W., Feifel B., Veronese M., Demetri G.D. A phase I study of nilotinib alone and in combination with imatinib (IM) in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST)-study update. J Clin Oncol 2007, 25(18S):10023.
11. Blay J.Y., Casali P.G., Reichardt P., von Mehren M., Debiec-Rychter M., Bailey S., Veronese M.L., Demetri G.D. A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): study update. J Clin Oncol 2008, 26(15S):10553.
12. Picard S., Titier K., Etienne G., Teilhet E., Ducint D., Bernard M.A., Lassalle R., Marit G., Reiffers J., Begaud B., Moore N., Molimard M., Mahon F.X. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109(8):3496-3499.
13. Larson R.A., Druker B.J., Guilhot F., O'Brien S.G., Riviere G.J., Krahnke T., Gathmann I., Wang Y. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study; IRIS (International Randomized Interferon vs STI571) Study Group. Blood 2008, 111(8):4022-4028.
14. Bakhtiar R., Khemani L., Hayes M., Bedman T., Tse F. Quantification of the anti-leukemia drug STI571 (Gleevec™) and its metabolite (CGP-74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2002, 28(6):1183-1194.
15. Guetens G., de Boeck G., Highlel M., Dumez H., van Oosterom A.T., de Bruijn E.A. Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry. J Chromatogr A 2003, 1020(1):27-34.
16. Parise R.A., Ramanathan R.K., Hayes M.J., Egorin M.J. Liquid chromatographic-mass spectrometric assay for quantification of imatinib and its main metabolite (CGP-74588) in plasma. J Chromatogr B: Analyt Technol Biomed Life Sci 2003, 791(1-2):39-44.
17. Frye R.F., Fitzgerald S.M., Lagattuta T.F., Hruska M.W., Egorin M.J. Effect of St. John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004, 76(4):323-329.
18. Titier K., Picard S., Ducint D., Teilhet E., Moore N., Berthaud P., Mahon F.-X., Molimard M. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2005, 27(5):634-640.
19. Solassol I., Bressolle F., Philibert L., Charasson V., Astre C., Pinguet F. Liquid chromatgraphy-electrospray mass spectometry determination of imatinib and its main metabolite, N-desmethyl-imatinib in human plasma. J Liquid Chromatogr Relat Tech 2006, 29:2957-2974.
20. Rochat B., Fayet A., Widmer N., Lahrichi S.L., Pesse B., Décosterd L.A., Biollez J. Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry. J Mass Spectrom 2008, 43(6):736-752.
21. Schleyer E., Pursche S., Köhne C.H., Schuler U., Renner U., Gschaidmeier H., Freiberg-Richter J., Leopold T., Jenke A., Bonin M., Bergemann T., le Coutre P., Gruner M., Bornhäuser M., Ottman O.G., Ehninger G. Liquid chromatographic method for detection and quantification of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. J Chromatogr B 2004, 799(1):23-36.
22. Velpandian T., Mathur R., Agarwal N.K., Arora B., Kumar L., Grupta S.K. Development and validation of a simple liquid chromatographic method with ultra-violet detection for the determination of imatinib in biological samples. J Chromatogr B 2004, 804(2):431-434.
23. Oostendorp R.L., Beijnen J.H., Schellens J.H.M., van Tellingen O. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. Biomed Chromatogr 2007, 21(7):747-754.
24. Pursche S., Ottman O.G., Ehninger G., Schleyer E. High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations. J Chromatogr B 2007, 852(1-2):208-216.
25. Prenen H., Guetens G., de Boeck G., Debiec-Rychter M., Manly P., Schöffski P., van Oosterom A.T., de Bruijn E. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 2006, 77(1):11-16.
26. ®, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection. J Chromatogr B 2007, 846(1-2):341-345.
27. Luo F.R., Yang Z., Camuso A., Smykla R., McGlinchey K., Fager K., Flefleh C., Castaneda S., Inigo I., Kan D., Wen M.-L., Kramer R., Blackwood-Chirchir A., Lee F.Y., Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 2006, 12(23):7180-7186.
28. Kamath A.V., Wang J., Lee F.Y., Marathe P.H. Preclinical pharmacokinetics and in vitro metabolism of dasatinb (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 2008, 61(3):365-376.
29. Mhaske D.V., Dhaneshwar S.R. Stability indicating HPTLC and LC determination of dasatinib in pharmaceutical dosage form. Chromatographia 2007, 66(1-2):95-102.
30. Hsieh Y., Galviz G., Zhou Q., Duncan C. Hydrophilic interaction liquid chromatography/tandem mass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma. Rapid Commun Mass Spectrom 2009, 23:1364-1370.
31. De Francia S., D'Avolio A., De Martino F., Pirro E., Baietto L., Siccardi M., Simiele M., Racca S., Saglio G., Di Carlo F., Di Perri G. J Chromatogr B: Analyt Technol Biomed Life Sci 2009, 877(18-19):1721-1726.
32. Haouala A., Zanolari B., Rochat B., Montemurro M., Zaman K., Duchosal M.A., Ris B.H., Leyvraz S., Widmer N., Decosterd L.A. J Chromatogr B 2009, 877:1982-1996.
33. Widmer N., Béguin A., Rochat B., Buclin T., Kovacsovics T., Duchosal M.A., Leyvraz S., Rosselet A., Biollaz J., Decosterd L.A. Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. J Chromatogr B: Analyt Technol Biomed Life Sci 2004, 803(April (2)):285-292.
34. Peng B., Hayes M., Resta D., Racine-Poon A., Druker B.J., Talpaz M., Sawyers C.L., Rosamilia M., Ford J., Lloyd P., Capdeville R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004, 22(5):935-942.
35. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., Tanaka C., Manley P., Rae P., Mietlowski W., Bochinski K., Hochhaus A., Griffin J.D., Hoelzer D., Albitar M., Dugan M., Cortes J., Alland L., Ottmann O.G. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354(24):2542-2551.
36. Accessed 5th November 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/GuidanGui/UCM070107.pdf.
37. Nicaise C., Wang X., Roy A., Pfister M., Chen T.T., Bleickardt E., Hochhaus A., Shah N.P., Nicolini F.E., Clark R.E., Saglio G. Dasatinib pharmacokinetics and exposure-response (E-R): relationships to efficacy and safety in patients with chronic myelogenous leukemia in chronic phase (CML-CP). Haematologica 2008, 93(S1):227.
38. Accessed 28th April 2009. http://www.emea.europa.eu/humandocs/PDFs/EPAR/tasigna/H-798-en6.pdf.